Abstract:Tumor heterogeneity results in more than 50% of hypermutated cancers failing to respond to standard immunotherapy. There are numerous challenges in terms of drug resistance, therapeutic strategies, and biomarkers in immunotherapy. In this study, we analyzed primary tumor samples from 533 cancer patients with six different cancer types using deep targeted sequencing and gene expression data from 78 colorectal cancer patients, whereby driver mutations, mutational signatures, tumor-associated neoantigens, and molecular cancer evolution were investigated. Driver mutations, including RET, CBL, and DDR2 gene mutations, were identified in the hypermutated cancers. Most hypermutated endometrial and pancreatic cancer patients carry genetic mutations in EGFR, FBXW7, and PIK3CA that are linked to immunotherapy resistance, while hypermutated head and neck cancer patients carry genetic mutations associated with better treatment responses, such as ATM and BRRCA2 mutations. APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) and DNA repair defects are mutational drivers that are signatures for hypermutated cancer. Cancer driver mutations and other mutational signatures are associated with sensitivity or resistance to immunotherapy, representing potential genetic markers in hypermutated cancers. Using computational prediction, we identified NF1 p.T700I and NOTCH1 p.V2153M as tumor-associated neoantigens, representing potential therapeutic targets for immunotherapy. Sequential mutations were used to predict hypermutated cancers based on genomic evolution. Using a logistic model, we achieved an area under the curve (AUC) = 0.93, accuracy = 0.93, and sensitivity = 0.81 in the testing set. The sequential patterns were distinct among the six cancer types, and the sequential mutation order of MSH2 and the coexisting BRAF genetic mutations influenced the hypermutated phenotype. The TP53~MLH1 and NOTCH1~TET2 sequential mutations impacted colorectal cancer survival (p-value = 0.027 and 0.0001, respectively) by reducing the expression of PTPRCAP (p-value = 1.06 × 10−6) and NOS2 (p-value = 7.57 × 10−7) in immunity. Sequential mutations are significant for hypermutated cancers, which are characterized by mutational heterogeneity. In addition to driver mutations and mutational signatures, sequential mutations in cancer evolution can impact hypermutated cancers. They characterize potential responses or predictive markers for hypermutated cancers. These data can also be used to develop hypermutation-associated drug targets and elucidate the evolutionary biology of cancer survival. In this study, we conducted a comprehensive analysis of mutational patterns, including sequential mutations, and identified useful markers and therapeutic targets in hypermutated cancer patients.

Fundamental immune-oncogenicity trade-offs define driver mutation fitness

Persistent mutation burden drives sustained anti-tumor immune responses

A tug-of-war between driver and passenger mutations in cancer and other adaptive processes

Tissue-Predisposition to Cancer Driver Mutations

Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers

Comprehensive and Integrated Genomic Characterization of Human Immunome in Cancer

and haploinsufficiency equip colonic epithelium for oncogenic transformation

Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers

The Immune Landscape of Cancer

High-throughput oncogene mutation profiling in human cancer

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

TP53 Gain-of-function Mutation Modulates the Immunosuppressive Microenvironment in Non-Hpv-associated Oral Squamous Cell Carcinoma.

Identification of essential genes for cancer immunotherapy

Protein structural context of cancer mutations reveals molecular mechanisms and identifies novel candidate driver genes

Abstract 2585: Mutant P53 Gains Oncogenic Functions Through a Cytosolic DNA Response

Differential Gain-of-Function Activity of Three P53 Hotspot Mutants in Vivo

Integrated Genomic Characterization of the Human Immunome in Cancer

Targeting a neoantigen derived from a common TP53 mutation

Melanoma-specific mutation hotspots in distal, non-coding, promoter-interacting regions implicate novel candidate driver genes

Accumulation of driver and passenger mutations during tumor progression

Spatially Resolved Analyses Link Genomic and Immune Diversity and Reveal Unfavorable Neutrophil Activation in Melanoma